Summary
Caladrius Biosciences Inc (Caladrius), formerly NeoStem, Inc., develops and manufactures cell therapy products. Its products are based on its proprietary technologies, Dendritic Cell-Tumor Cell technology; CD34 technology; and T Regulatory technology, for immuno-oncology, ischemic repair and immunomodulation. The company’s developmental pipeline products include CLBS20 (NBS20) for the treatment of metastatic melanoma, CLBS10 (formerly NBS10) for ST-elevation myocardial infarction and CLBS03 for type 1 diabetes. It offers services such as product and process development, engineering and automation, GMP manufacturing, cell and tissue processing, storage and distribution, and expert consulting and regulatory support. The company offers products and services to biotechnology, pharmaceutical and medical product companies, and leading academic research institutions. Caladrius is headquartered in Basking Ridge, New Jersey, the US.
Caladrius Biosciences Inc (CLBS) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Caladrius Biosciences Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Caladrius Biosciences Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Caladrius Biosciences Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Caladrius Biosciences Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
Caladrius Biosciences Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Caladrius Biosciences Inc, Medical Equipment, Deal Details 10
Partnerships 10
Caladrius Biosciences Enters into Research Agreement with University of Southern California and California Institute of Technology 10
NeoStem Enters into Co-Development Agreement with Invetech 11
Equity Offering 11
NeoStem Raises USD29 Million in Public Offering of Shares 11
NeoStem to Raise USD30 Million in Private Placement of Shares 13
NeoStem Completes Public Offering Of Shares For US$40.25 Million 14
NeoStem Files Registration Statement For Private Placement Of Shares For US$8 Million 15
NeoStem Completes Public Offering Of Shares For US$11.5 Million 15
NeoStem Completes Private Placement Of Common Stock For US$3 Million 17
NeoStem Completes Public Offering Of Units For US$6.8 Million 18
NeoStem Completes An Underwritten Public Offering Of Units For US$16.5 Million 19
Acquisition 21
Hitachi Chemical to Acquire Remaining 80.1% Interest in Progenitor Cell Therapy from Caladrius Biosciences 21
NeoStem Completes Acquisition Of California Stem Cell 22
Caladrius Biosciences Inc - Key Competitors 24
Key Employees 25
Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Mar 17, 2017: Caladrius Biosciences Announces 2016 Fourth Quarter and Full Year Financial Results 27
Nov 07, 2016: Caladrius Biosciences Reports 2016 Third Quarter Financial Results 29
Aug 09, 2016: Caladrius Biosciences Reports 2016 Second Quarter Financial Results 31
May 05, 2016: Caladrius Biosciences Reports 2016 First Quarter Financial Results 33
Mar 15, 2016: Caladrius Biosciences Announces 2015 Fourth Quarter and Full Year Financial Results 35
Corporate Communications 37
Oct 12, 2016: Caladrius Biosciences Appoints Gregory R. Brown, MD, to its Board of Directors 37
Jun 27, 2016: Caladrius Biosciences SVP and President of PCT, Robert Preti, PhD, Named Chairman of the Alliance for Regenerative Medicine 38
Other Significant Developments 39
Jan 06, 2016: Caladrius Tightens Strategic Focus and Provides 2016 Revenue Guidance 39
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41
List of Tables
Caladrius Biosciences Inc, Medical Equipment, Key Facts, 2015 1
Caladrius Biosciences Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 1
Caladrius Biosciences Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Caladrius Biosciences Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Caladrius Biosciences Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Caladrius Biosciences Inc, Deals By Market, 2011 to YTD 2017 8
Caladrius Biosciences Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Caladrius Biosciences Enters into Research Agreement with University of Southern California and California Institute of Technology 10
NeoStem Enters into Co-Development Agreement with Invetech 11
NeoStem Raises USD29 Million in Public Offering of Shares 11
NeoStem to Raise USD30 Million in Private Placement of Shares 13
NeoStem Completes Public Offering Of Shares For US$40.25 Million 14
NeoStem Files Registration Statement For Private Placement Of Shares For US$8 Million 15
NeoStem Completes Public Offering Of Shares For US$11.5 Million 15
NeoStem Completes Private Placement Of Common Stock For US$3 Million 17
NeoStem Completes Public Offering Of Units For US$6.8 Million 18
NeoStem Completes An Underwritten Public Offering Of Units For US$16.5 Million 19
Hitachi Chemical to Acquire Remaining 80.1% Interest in Progenitor Cell Therapy from Caladrius Biosciences 21
NeoStem Completes Acquisition Of California Stem Cell 22
Caladrius Biosciences Inc, Key Competitors 24
Caladrius Biosciences Inc, Key Employees 25
Caladrius Biosciences Inc, Other Locations 26
Caladrius Biosciences Inc, Subsidiaries 26
List of Figures
Caladrius Biosciences Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017 1
Caladrius Biosciences Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 1
Caladrius Biosciences Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 1
Caladrius Biosciences Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 1
Caladrius Biosciences Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Caladrius Biosciences Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017 6
Caladrius Biosciences Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Caladrius Biosciences Inc, Medical Equipment, Deals by Market, 2011 to YTD 2017 8
